Abstract: Provided are a computer program product, system, and method for verifying translations of text in a source language to target text in a target language. A source similarity score is calculated indicating a similarity between a first text and second text in a source language. A target similarity score is calculated between translated first text, comprising a translation of the first text in a target language, and translated second text, comprising a translation of the second text in the target language. A determination is made whether the translation of the first text to the translated first text is of an inappropriate translation quality based on the source similarity score and the target similarity score. Indication is made of indicating the inappropriate translation quality in response to determining the inappropriate translation quality.

Abstract: Provided herein are methods of treating cancer using agonistic antibodies that specifically bind to immunostimulatory receptors, wherein the antibodies are administered in an amount and/or frequency sufficient to achieve and/or maintain a receptor occupancy of less than about 80%, for example, a receptor occupancy of about 20% to about 80%. Also provided are methods of determining human doses for such agonistic antibodies, and methods for monitoring receptor occupancy of the agonistic antibodies in order to maintain effective antibody levels in, e.g., human patients.

Abstract: Provided herein are methods of treating cancer using agonistic antibodies that specifically bind to immunostimulatory receptors, wherein the antibodies are administered in an amount and/or frequency sufficient to achieve and/or maintain a receptor occupancy of less than about 80%, for example, a receptor occupancy of about 20% to about 80%. Also provided are methods of determining human doses for such agonistic antibodies, and methods for monitoring receptor occupancy of the agonistic antibodies in order to maintain effective antibody levels in, e.g., human patients. Also provided are methods of measuring soluble OX40 in a subject. Also provided are methods of treating cancer, comprising administering to the subject an effective amount of each of an anti-OX40 antibody and an anti-PD-1 antibody.

Abstract: The present disclosure provides anti-CD40 antibodies or antigen-binding fragments thereof, isolated polynucleotides encoding the same, pharmaceutical compositions comprising the same, and the uses thereof.

Abstract: Provided are methods for clinical treatment of malignant tumors (e.g., advanced solid tumors) using a combination of an OX40 agonist, a PD-1 pathway inhibitor, and a CTLA-4 inhibitor.

Abstract: Provided herein are methods of treating cancer using agonistic antibodies that specifically bind to immunostimulatory receptors, wherein the antibodies are administered in an amount and/or frequency sufficient to achieve and/or maintain a receptor occupancy of less than about 80%, for example, a receptor occupancy of about 20% to about 80%. Also provided are methods of determining human doses for such agonistic antibodies, and methods for monitoring receptor occupancy of the agonistic antibodies in order to maintain effective antibody levels in, e.g., human patients. Also provided are methods of measuring soluble OX40 in a subject. Also provided are methods of treating cancer, comprising administering to the subject an effective amount of each of an anti-OX40 antibody and an anti-PD-1 antibody.

Abstract: A method includes collecting information corresponding to a build environment in which a build result of a source code is generated, the collected information including one or more predefined build environment factors, and storing, in a repository, the collected information as a version of the build environment.

Abstract: A method includes collecting information corresponding to a build environment in which a build result of a source code is generated, the collected information including one or more predefined build environment factors, and storing, in a repository, the collected information as a version of the build environment.